BioProcess Insider

@BioProInsider

BioProcess Insider provides the latest news, views, and issues impacting the global biomanufacturing industry

Vrijeme pridruživanja: travanj 2018.

Tweetovi

Blokirali ste korisnika/cu @BioProInsider

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @BioProInsider

  1. proslijedio/la je Tweet
    3. velj

    Breaking: Catalent to buy Orgenesis' biz Masthercell for $315m - story Insider

    Poništi
  2. proslijedio/la je Tweet
    30. sij

    Just over a week ago we had our most loved & exciting Yacht Party for & ! What an amazing night where $10,000 was raised for the 🎉🥳

    Poništi
  3. proslijedio/la je Tweet
    30. sij

    Lack of good a factor for in investing $70-90m into internal PA gene therapy plant

    Poništi
  4. proslijedio/la je Tweet
    3. velj

    Oklahoma has introduced a bill intended to ban the state from prescribing, administering, and making medicinal products and vaccines containing human DNA

    Poništi
  5. proslijedio/la je Tweet
    30. sij

    VGXI will make Inovio Pharmaceuticals’ investigational as part of a collaborative effort to halt the progress of the that has recently emerged in China

    Poništi
  6. proslijedio/la je Tweet
    29. sij
    Poništi
  7. proslijedio/la je Tweet
    27. sij

    It's here! Falcon CEO Susan Nichols’ annual roundup of top events within the cell and gene therapy space in 2019, from Contains capacity, and M&A , but takes the top spot

    Poništi
  8. proslijedio/la je Tweet
    23. sij

    And here is the full story from courtesy of 'CDMO aims ‘big’ in $1.2bn push to deliver capacity to cell & gene space'

    Prikaži ovu nit
    Poništi
  9. proslijedio/la je Tweet
    22. sij

    FDA cell and gene therapy forecast ‘unlikely’ - the opinion from Phacilitate as number of commercialized therapeutics falls flat after dynamic 2017

    Poništi
  10. proslijedio/la je Tweet
    22. sij

    Mixture of pride of advancement but disappointment in relatively few commercial cell and gene products is the feeling at this year’s in miami. Article to come on

    Poništi
  11. proslijedio/la je Tweet
    21. sij

    iovance admits TIL therapies with 22 day manufacturing process and potential gene editing added will be very expensive, though refuses to say whether it will be Kymriah expensive or Zolgensma expensive, at

    Poništi
  12. proslijedio/la je Tweet
    21. sij

    Regeneron says it can now roll out a lot more bispecific antibody-based therapies including a new class of costimulatory bispecifics

    Poništi
  13. proslijedio/la je Tweet
    21. sij

    Genetic disease-focused firms need infrastructure says , which shared plans for a gene editing center of excellence at the conference

    Poništi
  14. proslijedio/la je Tweet
    14. sij

    Merck CEO Ken Frazier views 2023 as the year firm will satiate the “incredible” global demand for Gardasil

    Poništi
  15. proslijedio/la je Tweet
    9. sij

    French VC firm is raising over €200m in a 2nd dedicated fund focused on the and says the therapeutic space will mature within the next 3 years

    Poništi
  16. proslijedio/la je Tweet
    24. pro 2019.

    On the first day of Christmas my leading news site gave to me, a merger based on CAR-T... Check out festive look back at 2019

    Poništi
  17. 19. pro 2019.

    Orbiting Organoids: Research in Space to Unveil New Neurodegeneration Insight via

    Poništi
  18. proslijedio/la je Tweet
    19. pro 2019.

    Oxford Biomedica will keep supplying with the vectors needed to make Kymriah and other CAR-T products under a 5-year deal extension

    Poništi
  19. proslijedio/la je Tweet
    17. pro 2019.

    Hemophilia A-OK! Roche’s $4.3bn Spark buy - There is no risk of competitive harm between Roche’s approved hemophila A monoclonal antibody and Spark’s candidates, says

    Poništi
  20. proslijedio/la je Tweet
    16. pro 2019.

    a exclusive: WuXi Biologics establishes microbial fermentation platform after building up mammalian and services -

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·